#PAGE_PARAMS# #ADS_HEAD_SCRIPTS# #MICRODATA#

Treatment of the Choroidal Neovascular Membrane by Ranibizumab (Lucentis): A Case Report


Authors: P. Němec;  Ž. Benešová;  L. Hejsek
Authors‘ workplace: Oční klinika 1. LF UK a ÚVN, Praha, přednosta doc. MUDr. Jiří Pašta, CSc.
Published in: Čes. a slov. Oftal., 66, 2010, No. 3, p. 134-137
Category: Case Report

Overview

A 73-year-old woman presented with a best-corrected visual acuity of 6/9 in her right eye and 6/36 in her left eye. Fundus examination revealed signs of age related macular degeneration in both eyes. In her right eye it was just dry form of the disease, in left one an elevated lesion associated with retinal cystoid edema was detected. Ocular coherence tomography and fluorescein angiogram confirmed a subfoveal occult choroidal neovascular membrane. We decided for intravitreal ranibizumab (Lucentis, 0.5 mg) treatment. One month after first injection, best-corrected visual acuity improved to 6/15 in her left eye. After six months, best-corrected visual acuity further improved to 6/12, with complete resolution subretinal fluid on ocular coherence tomography.

Key words:
age related macular degeneration, occult choroidal neovascularization, anti-VEGF, ranibizumab


Sources

1. Bressler NM, Bressler SB, Fine SL.: Age-related macular degeneration.Surv Opthalmol 1988; 32: 375–413.

2. Bressler NM.: Age-related macular degeneration is the leading cause of blindness. JAMA 2004; 291: 1900–1901.

3. Brown DM, Kaiser PK, Michels M. et al.: Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 2006; 355: 1432–1444.

4. Hee MR, Baumal CR, Puliafito CA. et al.: Optical coherence tomography of age-related macular degeneration and choriodal neovascularization. Opthalmogy1996; 103:1260–1270.

5. Margherio RR, Margherio AR, DeSantis ME.: Laser treatments with verteporfirin therapy and its potential impact on retinal practices. Retina 2000; 20: 325–330.

6. Rosenfeld PJ, Heier JS, Hantsbarger G, Shams N.: Tolerability and efficacy of multiple escalating doses of ranibizumab (Lucentis) for neovascular age-related macular degeneration. Ophthalmology 2006; 113: 623–632

Labels
Ophthalmology

Article was published in

Czech and Slovak Ophthalmology

Issue 3

2010 Issue 3

Most read in this issue
Topics Journals
Login
Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.

Login

Don‘t have an account?  Create new account

#ADS_BOTTOM_SCRIPTS#